Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2026)
Argenx Se's (ARGX) quarterly Liabilities and Shareholders Equity came in at $10.0 billion in Q2 2026, up 39.81% YoY from $7.2 billion in Q2 2025, and up 15.54% on a QoQ basis from $8.7 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $10.0 billion in Q2 2026.
- Quarterly Liabilities and Shareholders Equity rose 39.81% year-over-year to $10.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.7 billion (up 39.89% YoY) and the FY2025 annual result came in at $8.7 billion, up 39.99% from the prior year.
- Liabilities and Shareholders Equity grew to $10.0 billion in Q2 2026, from $8.7 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $10.0 billion in Q2 2026 to a low of $3.1 billion in Q4 2022.
- A 5-year average of $5.7 billion and a median of $4.8 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity decreased 1.71% — and 2024, when it surged 50.18%.
- Tracing ARGX's Liabilities and Shareholders Equity over 5 years: stood at $3.1 billion in 2022, then surged by 44.93% to $4.5 billion in 2023, then soared by 36.55% to $6.2 billion in 2024, then surged by 39.99% to $8.7 billion in 2025, then rose by 15.54% to $10.0 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $10.0 billion (Q2 2026), $8.7 billion (Q4 2025), and $7.2 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 7.87 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.03 Bn |
| Dec 31, 2025 | 8.68 Bn |
| Jun 30, 2025 | 7.18 Bn |
| Dec 31, 2024 | 6.20 Bn |
| Jun 30, 2024 | 4.80 Bn |
| Dec 31, 2023 | 4.54 Bn |
| Jun 30, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.25 Bn |
| Dec 31, 2021 | 2.85 Bn |
| Jun 30, 2021 | 3.21 Bn |
| Dec 31, 2020 | 2.21 Bn |
| Jun 30, 2020 | 2.23 Bn |
| Dec 31, 2019 | 1.59 Bn |
| Jun 30, 2019 | 1.13 Bn |
| Dec 31, 2018 | 660.25 Mn |
| Jun 30, 2018 | 429.66 Mn |
| Dec 31, 2017 | 436.72 Mn |
| Jun 30, 2017 | 203.95 Mn |
| Dec 31, 2016 | 114.20 Mn |